New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
arcticnovartis
- ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1
- Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed1
